Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

19.1K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
19.1K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Neural Regulation01:37

Neural Regulation

45.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
45.2K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.5K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RNA Therapeutics Targeting Skeletal Muscle: Emerging Antisense and Gene-Modifying Strategies.

Biomolecules·2026
Same author

Building CRISPR-Based Gene-Editing Platforms for Personalized Medicine: The Next Step in Interventional Genetics.

Genes·2026
Same author

The Multi-System Roles of Dp71 Dystrophin Isoforms in Duchenne Muscular Dystrophy.

Muscles (Basel, Switzerland)·2026
Same author

FDA-approved antisense oligonucleotide therapies for duchenne muscular dystrophy: current status and future outlook.

RNA biology·2026
Same author

Single-base 2'OMe-modified LNA and MOE gapmers selectively silence <i>ACVR1</i> <sup><i>R206H</i></sup> in fibrodysplasia ossificans progressiva.

Molecular therapy. Nucleic acids·2026
Same author

DMD-Null mice exhibit severe muscle weakness, impaired regeneration, and deficient satellite cell function.

Proceedings of the National Academy of Sciences of the United States of America·2026

Related Experiment Video

Updated: Apr 18, 2026

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
07:47

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Published on: October 29, 2019

19.9K

Antisense therapy in neurology.

Joshua J A Lee1, Toshifumi Yokota2

  • 1Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, 8812-112 St, Edmonton T6G 2H7, Canada. jjlee@ualberta.ca.

Journal of Personalized Medicine
|January 7, 2015
PubMed
Summary

Antisense therapy utilizes DNA-like molecules to treat neurological disorders. This approach shows promise for conditions like spinal muscular atrophy and Huntington's disease, with early trials yielding encouraging results.

More Related Videos

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
04:45

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

365
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

62.4K

Related Experiment Videos

Last Updated: Apr 18, 2026

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
07:47

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Published on: October 29, 2019

19.9K
Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
04:45

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

365
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

62.4K

Area of Science:

  • Neurology
  • Molecular Biology
  • Genetics

Background:

  • Antisense oligonucleotides (ASOs) are short, DNA-like molecules designed to target and modify gene expression.
  • Neurodegenerative and neuromuscular disorders represent a significant unmet medical need, with limited effective treatment options.
  • Recent advancements in antisense technology have opened new therapeutic avenues for these complex diseases.

Purpose of the Study:

  • To review the current progress and potential of antisense therapy in treating neurological disorders.
  • To highlight specific neurodegenerative and neuromuscular conditions that are promising targets for antisense oligonucleotide intervention.
  • To consolidate findings from pre-clinical and clinical trials evaluating antisense therapies in neurology.

Main Methods:

  • Literature review of pre-clinical and clinical studies on antisense therapy in neurological diseases.
  • Analysis of reported outcomes for various antisense oligonucleotide-based treatments.
  • Focus on conditions including spinal muscular atrophy, Huntington's disease, and amyotrophic lateral sclerosis.

Main Results:

  • Antisense therapy has demonstrated encouraging early results in pre-clinical and clinical trials.
  • Several neurodegenerative and neuromuscular disorders, such as SMA, HD, ALS, DMD, FCMD, dysferlinopathy, and DM, are identified as promising targets.
  • Ongoing research indicates a growing potential for ASO-based treatments in managing these conditions.

Conclusions:

  • Antisense therapy is an emerging and promising strategy for treating a range of neurological and neuromuscular disorders.
  • The application of antisense oligonucleotides in neurology is rapidly advancing, offering new hope for patients.
  • Continued research and clinical trials are crucial for realizing the full therapeutic potential of antisense therapy in neurological disease management.